{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Virtakoivu R"],"funding":["European Union&apos;s Horizon 2020 research and innovation program","Cancer Research UK","Cancer Foundation Finland sr"],"pagination":["4205-4220"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401456"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(15)"],"pubmed_abstract":["<h4>Purpose</h4>Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition of the macrophage scavenger receptor Clever-1 has shown benefit in inducing CD8<sup>+</sup> T-cell-mediated antitumor responses in mouse models of cancer, which supports the clinical development of Clever-1-targeting antibodies for cancer treatment.<h4>Patients and methods</h4>In this study, we analyzed the mode of action of a humanized IgG4 anti-Clever-1 antibody, FP-1305 (bexmarilimab), both <i>in vitro</i> and in patients with heavily pretreated metastatic cancer (<i>n</i> = 30) participating "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial."],"pmcid":["PMC9401456"],"funding_grant_id":["200086","C53575/A29959","200096","960914","200081","29959"],"pubmed_authors":["Shetty S","Robbrecht D","Hollmen M","Viitala M","Lonnberg T","de Jonge MJA","Virtakoivu R","Minchom A","Ma YT","Rannikko JH","Jaakkola P","Bono P","Koivunen J","Mandelin J","Takeda A","Jalkanen S","Skytta T","Vaura F","Pasanen A","Karvonen MK"],"additional_accession":[]},"is_claimable":false,"name":"Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.","description":"<h4>Purpose</h4>Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition of the macrophage scavenger receptor Clever-1 has shown benefit in inducing CD8<sup>+</sup> T-cell-mediated antitumor responses in mouse models of cancer, which supports the clinical development of Clever-1-targeting antibodies for cancer treatment.<h4>Patients and methods</h4>In this study, we analyzed the mode of action of a humanized IgG4 anti-Clever-1 antibody, FP-1305 (bexmarilimab), both <i>in vitro</i> and in patients with heavily pretreated metastatic cancer (<i>n</i> = 30) participating ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2026-05-10T06:44:19.657Z","creation":"2025-04-04T13:08:55.812Z"},"accession":"S-EPMC9401456","cross_references":{"pubmed":["34078651"],"doi":["10.1158/1078-0432.CCR-20-4862"]}}